Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (ODAC)

April 16, 2008

FDA

Disclaimer

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).

FDA Briefing Material (pdf)